Abnormal movement in US stocks | The first "oral version of weight loss drug" approved, Novo Nordisk (NVO.US) rose more than 8% before the market opened.

According to the Wise Finance app, on Tuesday, Novo Nordisk (NVO.US) rose more than 8% in pre-market trading, reaching $52.29. In terms of news, the US FDA has approved Novo Nordisk's first oral GLP-1 weight loss drug, giving it an advantage in competition with Eli Lilly. This oral version of Wegovy will be launched in the US in early January next year, with an initial cash price of $149 per month. Clinical data shows that it can help patients lose weight by up to 16.6% and reduce cardiovascular risk.